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A commentary on
The beginning of the road for non-
coding RNAs in normal hematopoiesis
and hematologic malignancies
by Heuston, E. F., Lemon, K. T., and
Arceci, R. J. (2011). Front. Genet. 2:94. doi:
10.3389/fgene.2011.00094
The human genome encodes∼20,000 pro-
teins; however, protein-coding genes rep-
resent <2% of the total genome (Gibb
et al., 2011). Since this discovery, sev-
eral studies have pointed out that at least
90% of the genome is actively transcribed
(Birney et al., 2007; Costa, 2010). This field
provoked a spirited debate, which is evi-
dent from the number of original articles,
reviews, letter to the editors, commen-
taries, and rebuttals.
Many long non-coding RNAs (lncR-
NAs), ranging from 0.2 to ∼100 kilobases
(kb) in length, are transcribed from
the genome. LncRNAs affect various
cellular functions such as gene reg-
ulation, genomic imprinting, RNA
maturation, and translation (Wang and
Chang, 2011). In addition, the differential
expression of lncRNAs has recently been
Table 1 | Expression level of the lncRNAs in Leukemia (the results are expressed as fold change
between cancer and normal tissues or cancer subtypes).
lncRNA State 1 State 2 Fold P-value
(Up-regulated) (Down-regulated) change
MEG3 AML Normal 3.592 0.004
FAB M3 Other FAB subtypes 14.617 1.23 × 10−7
H19 AML Normal 1.932 5.4 × 10−4
FAB M3 Other FAB subtypes 4.271 2.26 × 10−4
AML ALL 2.664 2 × 10−6
UCA1 FAB M2 Other FAB subtypes 1.885 3.33 × 10−4
The data were obtained from the Oncomine Database.
linked to carcinogenesis, including gas-
tric cancer (Hajjari et al., 2013). In recent
reports, lncRNAs have been attributed to
oncogenic and/or tumor suppressor roles
(Reviewed in Gibb et al., 2011; Qiu et al.,
2013). Taken together, these reports sup-
port the possible involvement of lncRNAs
in the initiation and/or progression of
breast, colorectal, liver, lung, and gastric
cancers (Hajjari and Khoshnevisan, 2013).
However, little is known about the poten-
tial role of lncRNAs in leukemia. In fact,
there is a paucity of reports on the char-
acterization of lncRNAs in this type of
cancer.
In the December 2011 edition of
Frontiers in Genetics, Heuston et al. (2011)
published a review on non-coding RNAs
in hematologic malignancies. They high-
lighted the potential roles for non-coding
RNAs including microRNAs and lncR-
NAs in the development of acute and
chronic leukemia. While this is the only
review that described the expression pat-
terns of ncRNAs in leukemia, it may pro-
vide a foundation for future research in
this field.
Heuston et al., referred to several
reports on lncRNAs such as ANRIL,
lncRNA-P21, MEG3, Dleu2, HOTAIRM1,
EGO, and lncRNA-a7 in leukemia, high-
lighting the potential benefit of research
on lncRNAs for the development of much
needed diagnostic, prognostic, and ther-
apeutic targets (Heuston et al., 2011).
In addition, based on the previous stud-
ies, Heuston et al., proposed to study
more about the functional role of MEG3
in leukemia. In our opinion, this review
provides an overview of the published
reports on the subject and represents a
suitable guide for researchers involved
in the field of molecular pathology of
leukemia.
To test if any prior evidence on the
potential role of lncRNAs in leukemia pro-
gression existed, we queried the Oncomine
Database (www.oncomine.org) for five
lncRNAs: HOTAIR, ANRIL, MEG3, H19,
and UCA1. All five lncRNAs were among
the most cited lncRNAs associated with a
potential role in cancer.
We found that two lncRNAs includ-
ing MEG3 and H19 are up-regulated in
acute myeloid leukemia (AML) cancer
compared to normal blood cells (Fold
change > 1.5, P-value < 0.01). As pre-
sented in Table 1, the results showed that
H19, UCA1, and MEG3 are up-regulated
in French-American-British (FAB) clas-
sification subtypes M3, M2, and M3,
respectively. The expression of H19 is
up-regulated in AML compared to acute
lymphoblastic leukemia (ALL). In con-
clusion, taken together, the review from
Heuston et al. and our data shed lights
on the roles of lncRNAs in different
types of leukemia and may prove use-
ful for the development of molecu-
lar diagnosis and targeted therapy for
leukemia.
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